Back to Search Start Over

Abstract 10454: Heart Failure With Recovered Ejection Fraction is Good Therapeuticmerkmal for Adaptive-Servo Ventilation Therapy in Patients With Heart Failure

Authors :
FUJII, TAKAAKI
Takama, Noriaki
Iwai, Ryutarou
KODAMA, CHIKA
TAKIZAWA, DAIKI
Yuasa, Naoki
Amanai, Shiro
Kuno, Takahiro
Harada, Tomonari
Hasegawa, Hiroshi
Kobari, Takashi
Ishibashi, Yohei
Aihara, Kazufumi
Sorimachi, Hidemi
Tamura, Shuntaro
Kato, Toshimitsu
Obokata, Masaru
Ohyama, Yoshiaki
Koitabashi, Norimichi
Kaneko, Yoshiaki
Ishii, Hideki
Source :
Circulation (Ovid); November 2022, Vol. 146 Issue: Supplement 1 pA10454-A10454, 1p
Publication Year :
2022

Abstract

Introduction:Heart failure with recovered ejection fraction (HFrecEF) is a complex clinical entity in which biology and clinical management. Previous clinical trial showed adaptive-servo ventilation (ASV) therapy is harmful for patient with heart failure with reduced ejection fraction (HFrEF), whereas we can initiate ASV for patients with HFrEF by adhering rigidly to Japanese statement about the proper use of ASV for HF.Hypothesis:It is still unclear whether ASV therapy is really harmful in patients with HFrecEF. Our aim is to estimate that ASV therapy is really harmful in patients with HFrecEF by estimating biomarkers and fatal cardiovascular events.Methods:The study group consisted of 78 patients with HF (age;70±12 years). Baseline LVEF was 27.8±8.5%. After optimal medical therapy, ASV was initiated as an additional HF treatment. After 6-month follow-up, we classified into 2 groups by result of LVEF after ASV therapy. Group A (n=20) was categorized as HFrecEF {low pre-LVEF (<45%) and improved post-LVEF (≧45%)}, Group B (n=58) was categorized as HFrEF {low pre-LVEF (<45%) and not improved post-LVEF (<45%)}. We estimate the changes of BNP and fatal cardiovascular events after ASV therapy.Results:Before ASV therapy, BNP did not show significant difference in 2 groups {Group A: 439(149-1344) pg/ml vs. Group B: 531(265-892) pg/ml, p=0.73}. After ASV therapy, the changes of BNP showed significant differences (Figure 1A), LVEF also showed significant differences in 2 groups (Group A: 52.3±7.5% vs. Group B: 30.8±3.7%, p=0.039). The fatal cardiovascular events rate after three-year follow-up showed significant good prognosis in Group A (Figure 1B).Conclusions:Our study showed that approximately one in four patients can change from HFrEF to HFrecEF, and ASV is acceptable and effective treatment for patients with HFrecEF by contributing to low fatal cardiovascular events and improvement of BNP level.

Details

Language :
English
ISSN :
00097322 and 15244539
Volume :
146
Issue :
Supplement 1
Database :
Supplemental Index
Journal :
Circulation (Ovid)
Publication Type :
Periodical
Accession number :
ejs61503717
Full Text :
https://doi.org/10.1161/circ.146.suppl_1.10454